## VRTX: Vertex Pharmaceuticals Incorpor - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($428.54)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Texas Permanent School Fund Corp Sells 9,892 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251216T123405 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly reduced its stake in Vertex Pharmaceuticals (VRTX) by selling 9,892 shares, representing a 35.4% decrease in its holdings. This divestment comes as company insiders have also been active sellers, with EVP Charles F. Wagner Jr. and Chairman Jeffrey M. Leiden collectively disposing of over 77,000 shares in December. Despite these insider sales and institutional reductions, Vertex Pharmaceuticals recently exceeded Q2 earnings and revenue expectations, maintaining a "Moderate Buy" consensus rating among analysts with an average price target of $498.42.

**2. Corient Private Wealth LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251217T085659 | Somewhat-Bearish | Relevance: 99%
- Corient Private Wealth LLC reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% in the second quarter, selling 3,734 shares and leaving them with 102,816 shares valued at $45.77 million. Other institutional investors also made new investments in VRTX shares, while company insiders, including Chairman Jeffrey M. Leiden and EVP Charles F. Wagner, Jr., sold significant portions of their holdings. Analysts have a "Moderate Buy" rating on Vertex Pharmaceuticals with an average price target of $498.42.

**3. Shorepoint Capital Partners LLC Invests $4.08 Million in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251216T122505 | Somewhat-Bullish | Relevance: 97%
- Shorepoint Capital Partners LLC has acquired a new stake of 10,405 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $4.08 million. This investment comes amidst significant insider selling, with the Chairman and EVP liquidating shares worth over $35 million in total. Despite these insider transactions, Vertex Pharmaceuticals reported strong quarterly earnings, beating analyst expectations for both EPS and revenue, and maintains an average analyst rating of "Moderate Buy."

**4. National Bank of Canada FI Acquires 99,751 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251215T102504 | Somewhat-Bullish | Relevance: 96%
- National Bank of Canada FI significantly increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 70.9% in the second quarter, acquiring an additional 99,751 shares. This brings their total holdings to 240,378 shares, valued at approximately $107.0 million. The company's stock generally maintains a "Moderate Buy" consensus from analysts, despite recent insider share sales totaling 151,073 shares.

**5. Castleark Management LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251215T091141 | Neutral | Relevance: 92%
- Castleark Management LLC significantly reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 98.4% in Q2, selling over 46,000 shares. Despite this, major institutional investors like Norges Bank and Vanguard Group increased their holdings, bringing institutional ownership to nearly 91%. Conversely, company insiders, including Chairman Jeffrey M. Leiden, engaged in substantial selling of shares.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $515 | $460 | +12% |
| 2025-12-05 | Morgan Stanley | $564 | $516 | +9% |
| 2025-12-03 | Morgan Stanley | $516 | $438 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-03 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($3.52M) |
| Sells | 10 ($11.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Capital World Invest: 10.2% (-9.8%)
- Vanguard Group Inc: 9.5% (+1.0%)
- Blackrock Inc.: 8.8% (+1.7%)
- Capital Research Glo: 6.5% (+2.8%)
- JPMORGAN CHASE & CO: 5.1% (+119.3%)

### Key Risks

1. Heavy insider selling: $11M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Momentum building: MRS_10 improving +2.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Forward P/E 22.2x stretched relative to 10% growth. Quality metrics strong (ROE 22%, ROA 12%, margin 31%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.44), $1.1B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($11.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $115.3B |
| Beta | 0.32 |
| 52W Range | $362.50 - $519.68 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | 22.2 |
| Current P/E | 24.4 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.1% to 2.9% (+2.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.1pp (needs >3.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: -STN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.89% (CS: 56) | Neutral |
| RSI_14 | 57.1 | Neutral |
| MACD Histogram | 0.35 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 1.018x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $449.52
- **Stop Loss:** $428.54 (4.7% risk)
- **Target:** $470.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 51
- **Position Value:** $22,925.52
- **Portfolio %:** 22.93%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-09 (Est: $5.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.58 | $4.80 | +4.9% |
| 2025Q2 | $4.25 | $4.52 | +6.3% |
| 2025Q1 | $4.29 | $4.06 | -5.4% |
| 2024Q4 | $4.02 | $3.98 | -1.0% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_10*